US2004058884A1PendingUtilityA1

Tenasin-C nucleic acid ligands

53
Priority: Jun 11, 1990Filed: May 1, 2003Published: Mar 25, 2004
Est. expiryJun 11, 2010(expired)· nominal 20-yr term from priority
Inventors:Brian HickeStephen WarrenDavid ParmaLarry Gold
A61P 35/00A61P 9/00A61P 9/10A61P 17/06A61P 17/00C12N 2310/321G01N 33/68C12N 2310/3517G01N 2333/503A61K 47/549C12N 2310/3183G01N 2333/62C07H 19/06A61K 47/54G01N 2333/8125G01N 2333/575C12Q 2600/158C12N 2310/13G01N 2333/976C12N 9/1276C12Q 2541/101G01N 33/76G01N 33/531C07H 19/10C40B 40/00C12N 2310/317C07H 21/00B82Y 5/00G01N 2333/96433C12Q 1/37C12N 2310/322C12N 15/115G01N 2333/96455A61K 38/00G01N 2333/16A61K 2123/00C12Q 1/6883G01N 2333/9726C07K 14/001G01N 2333/163G01N 2333/974G01N 33/532C12N 15/1048F02B 2075/027C12N 2310/53G01N 33/535G01N 2333/966G01N 33/56988A61K 47/547
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods are described for the identification and preparation of nucleic acid ligands to tenascin-C. Included in the invention are specific RNA ligands to tenascin-C identified by the SELEX method. Further included in the invention are methods for detecting the presence of a disease condition in a biological tissue in which tenascin-C is expressed.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for delivering a therapeutic agent to a patient having a disease in which tecnascin-C is expressed, comprising: 
 covalently attaching a tenascin-C nucleic acid ligand to a therapeutic agent to form a complex, and administering said complex to said patient.    
     
     
         2 . The method of  claim 1 , wherein the disease in which tenascin-C is expressed is selected from the group consisting of cancer, hyperproliferative skin diseases, and arthrosclerosis.  
     
     
         3 . The method of  claim 2 , wherein the cancer is selected from the group consisting of lung cancer, breast cancer, prostate cancer, colon cancer, astrocytomas, glioblastomas, melanomas, and sarcomas.  
     
     
         4 . The method of  claim 1 , wherein the disease in which tenascin-C is expressed is a disease in which tenascin-C is overexpressed.  
     
     
         5 . The method of  claim 1 , wherein the attachment of the tenascin-C nucleic acid ligand to a therapeutic agent is accomplished through the use of a linker.  
     
     
         6 . The method of  claim 5 , wherein said linker has the structure:  
       
         
           
           
               
               
           
         
       
     
     
         7 . The method of  claim 6 , wherein the tenascin-C nucleic acid ligand is single stranded.  
     
     
         8 . The method of  claim 7 , wherein the tenascin-C nucleic acid ligand is RNA.  
     
     
         9 . The method of  claim 8 , wherein the tenascin-C nucleic acid ligand is comprised of 2′-fluoro (2′-F) modified nucleotides.  
     
     
         10 . The method of  claim 1 , wherein the tenascin-C nucleic acid ligand is selected from the group consisting of SEQ ID NO:4-65.

Join the waitlist — get patent alerts

Track US2004058884A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.